Repurposed Spinal Cord Injury Drug Shows Promise Against Alzheimer's in Mouse Studies
A drug originally developed for spinal cord injury could potentially be repurposed to treat Alzheimer's disease, according to new research published in Science Daily.
The compound, called KCL-286, demonstrated promising results in mouse studies. Unlike many existing Alzheimer's treatments that focus primarily on amyloid plaques or tau tangles, KCL-286 appears to work through multiple mechanisms. In the studies, the drug repaired dangerous DNA damage in brain cells and reduced inflammation—a key contributor to neurodegenerative decline.
The research is particularly noteworthy because KCL-286 has already cleared an initial human safety trial, having been tested for its original intended use. This prior safety testing could potentially accelerate the drug's path into Alzheimer's-specific clinical trials, cutting down on development time that typically spans years or even decades.
Researchers involved in the study emphasized that targeting DNA repair and inflammation represents a broader approach to addressing Alzheimer's pathology. By attacking the disease through several pathways simultaneously, the drug may prove more effective than treatments targeting a single mechanism.
While the results are encouraging, experts note that findings in mouse models do not always translate directly to human patients. Further clinical testing will be needed to confirm whether the benefits observed in the study hold true for people living with Alzheimer's disease.